We are live on
!
Find out more
KAM
Krensavage Asset Management Portfolio holdings
AUM
$256M
1-Year Est. Return
69.63%
This Fund
S&P 500
This Quarter
Est. Return
+4.24%
1 Year Est. Return
+69.63%
3 Year Est. Return
+113.28%
5 Year Est. Return
+196.5%
10 Year Est. Return
+463.27%
AUM
$282M
AUM Growth
+$10.2M
(+3.8%)
Cap. Flow
-$1M
Cap. Flow
% of AUM
-0.36%
Top 10 Holdings %
Top 10 Hldgs %
99.48%
Holding
16
New
4
Increased
3
Reduced
3
Closed
4
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Jazz Pharmaceuticals
JAZZ
|
+$12.5M |
| 2 |
Sanofi
SNY
|
+$7.35M |
| 3 |
MASI
Masimo
MASI
|
+$746K |
| 4 |
MURA
Mural Oncology
MURA
|
+$365K |
| 5 |
Alkermes
ALKS
|
+$311K |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Embecta
EMBC
|
+$17.5M |
| 2 |
EGRX
Eagle Pharmaceuticals, Inc.
EGRX
|
+$1.78M |
| 3 |
Vanda Pharmaceuticals
VNDA
|
+$1.56M |
| 4 |
Cardinal Health
CAH
|
+$977K |
| 5 |
Kodiak Sciences
KOD
|
+$616K |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1
Exelixis
EXEL
$13.3B
| $45.6M | 16.16% |
1,899,079
-72
| -0% | -$1.56K |
|
2
United Therapeutics
UTHR
$25.8B
| $44.2M | 15.67% |
200,872
-350
| -0.2% | -$80.7K |
|
3
Biogen
BIIB
$30B
| $41.5M | 14.73% |
160,480
| – | – |
|
4
Regeneron Pharmaceuticals
REGN
$78.5B
| $41.5M | 14.73% |
47,256
| – | – |
|
|
5
Cardinal Health
CAH
$53.9B
| $28.4M | 10.07% |
281,476
-9,843
| -3% | -$977K |
|
|
TARO
6
DELISTED
Taro Pharmaceutical Industries Ltd.
TARO
| $27M | 9.58% |
646,453
+5,718
| +0.9% | +$211K |
|
|
7
Alkermes
ALKS
$8.22B
| $25.5M | 9.04% |
918,038
+11,978
| +1% | +$311K |
|
|
8
Jazz Pharmaceuticals
JAZZ
$15.9B
| $12.3M | 4.36% |
+100,000
| New | +$12.5M |
|
|
9
Sanofi
SNY
$103B
| $7.48M | 2.65% |
+150,400
| New | +$7.35M |
|
10
Enanta Pharmaceuticals
ENTA
$366M
| $6.99M | 2.48% |
742,824
+7,721
| +1% | +$71.9K |
|
|
MASI
11
DELISTED
Masimo
MASI
| $938K | 0.33% |
+8,000
| New | +$746K |
|
|
MURA
12
DELISTED
Mural Oncology
MURA
| $538K | 0.19% |
+90,833
| New | +$365K |
|
|
13
Embecta
EMBC
$216M
| – | – |
-1,164,876
| Closed | -$17.5M |
|
|
14
Kodiak Sciences
KOD
$2.6B
| – | – |
-342,312
| Closed | -$616K |
|
|
15
Vanda Pharmaceuticals
VNDA
$307M
| – | – |
-360,429
| Closed | -$1.56M |
|
|
EGRX
16
DELISTED
Eagle Pharmaceuticals, Inc.
EGRX
| – | – |
-112,666
| Closed | -$1.78M |
|
Similar funds
CIA
2
CIM
JFG
PIP
LRIC
GAMC
TIA
Krensavage Asset Management's Q4 2023 Portfolio in Review
As of Q4 2023, Krensavage Asset Management held 16 positions worth $282M, up 3.8% from $272M the previous quarter. Its ten largest holdings account for 99% of the portfolio.
Krensavage Asset Management's Q4 2023 filing shows 4 new, 3 increased, 3 reduced and 4 closed positions. Its largest new stake was Jazz Pharmaceuticals: 100,000 shares worth $12.3M. The largest sale was Embecta, an estimated $17.5M.
By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.
- Krensavage Asset Management's largest Q4 2023 buy was Jazz Pharmaceuticals: 100,000 shares worth $12.3M.
- Krensavage Asset Management added most to Alkermes in Q4 2023, an estimated $311K increase.
- Krensavage Asset Management's biggest Q4 2023 reduction was Cardinal Health, cutting an estimated $977K.
- Krensavage Asset Management fully exited Embecta in Q4 2023, selling an estimated $17.5M.
- Krensavage Asset Management's ten largest holdings make up 99% of its $282M portfolio in Q4 2023.
- Krensavage Asset Management opened 4 new positions and closed 4 in Q4 2023.
- Krensavage Asset Management's portfolio value rose 3.8% quarter-over-quarter to $282M.
Based on Krensavage Asset Management's 13F filing for Q4 2023, filed 14 Feb 2024.